PMID- 35986429
OWN - NLM
STAT- MEDLINE
DCOM- 20220823
LR  - 20220906
IS  - 2054-9369 (Electronic)
IS  - 2095-7467 (Print)
IS  - 2054-9369 (Linking)
VI  - 9
IP  - 1
DP  - 2022 Aug 20
TI  - DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits.
PG  - 45
LID - 10.1186/s40779-022-00410-2 [doi]
LID - 45
AB  - Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors 
      are commonly used treatments for patients with type 2 diabetes mellitus (T2DM). 
      Both anti-diabetic treatments function by playing key modulatory roles in the 
      incretin system. Though these drugs have been deemed effective in treating T2DM, 
      the Food and Drug Administration (FDA) and some members of the scientific 
      community have questioned the safety of these therapeutics relative to important 
      cardiovascular endpoints. As a result, since 2008, the FDA has required all new 
      drugs for glycemic control in T2DM patients to demonstrate cardiovascular safety. 
      The present review article strives to assess the safety and benefits of 
      incretin-based therapy, a new class of antidiabetic drug, on the health of 
      patient cardiovascular systems. In the process, this review will also provide a 
      physiological overview of the incretin system and how key components function in 
      T2DM.
CI  - (c) 2022. The Author(s).
FAU - Razavi, Michael
AU  - Razavi M
AD  - Tulane University School of Medicine, New Orleans, LA, 70112, USA.
FAU - Wei, Ying-Ying
AU  - Wei YY
AD  - Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical 
      College of Huazhong University of Science and Technology, 1095 Jiefang Ave, 
      Wuhan, 430032, China.
FAU - Rao, Xiao-Quan
AU  - Rao XQ
AD  - Department of Cardiovascular Medicine, Tongji Hospital, Tongji Medical College of 
      Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan, 430032, 
      China. xqrao@tjh.tjmu.edu.cn.
FAU - Zhong, Ji-Xin
AU  - Zhong JX
AUID- ORCID: 0000-0002-3534-7480
AD  - Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical 
      College of Huazhong University of Science and Technology, 1095 Jiefang Ave, 
      Wuhan, 430032, China. zhongjixin620@163.com.
AD  - Institute of Allergy and Clinical Immunology, Tongji Hospital, Tongji Medical 
      College of Huazhong University of Science and Technology, Wuhan, 430032, China. 
      zhongjixin620@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220820
PL  - England
TA  - Mil Med Res
JT  - Military Medical Research
JID - 101643181
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Incretins)
SB  - IM
MH  - *Cardiovascular System
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Dipeptidyl-Peptidase IV Inhibitors/adverse effects
MH  - Glucagon-Like Peptide-1 Receptor/agonists/therapeutic use
MH  - Humans
MH  - Incretins/adverse effects
MH  - United States
PMC - PMC9392232
OTO - NOTNLM
OT  - Cardiovascular outcome
OT  - Dipeptidyl peptidase-4 inhibitors
OT  - Glucagon-like peptide-1 receptor agonists
OT  - Type 2 diabetes mellitus
COIS- The authors declare that there is no conflict of interest in this manuscript.
EDAT- 2022/08/20 06:00
MHDA- 2022/08/24 06:00
PMCR- 2022/08/20
CRDT- 2022/08/19 23:44
PHST- 2022/01/06 00:00 [received]
PHST- 2022/08/08 00:00 [accepted]
PHST- 2022/08/19 23:44 [entrez]
PHST- 2022/08/20 06:00 [pubmed]
PHST- 2022/08/24 06:00 [medline]
PHST- 2022/08/20 00:00 [pmc-release]
AID - 10.1186/s40779-022-00410-2 [pii]
AID - 410 [pii]
AID - 10.1186/s40779-022-00410-2 [doi]
PST - epublish
SO  - Mil Med Res. 2022 Aug 20;9(1):45. doi: 10.1186/s40779-022-00410-2.